RT Journal Article SR Electronic T1 First Experiences with 177Lu-PSMA Therapy in Combination with Pembrolizumab or After Pretreatment with Olaparib in Single Patients JF Journal of Nuclear Medicine JO J Nucl Med FD Society of Nuclear Medicine SP 975 OP 978 DO 10.2967/jnumed.120.249029 VO 62 IS 7 A1 Vikas Prasad A1 Friedemann Zengerling A1 Jochen P. Steinacker A1 Christian Bolenz A1 Meinrad Beer A1 Thomas Wiegel A1 Matthias Eiber A1 Neil Fleshner A1 Ambros J. Beer YR 2021 UL http://jnm.snmjournals.org/content/62/7/975.abstract AB Synergistic effects of immunotherapy with pembrolizumab or drugs targeting DNA damage, such as olaparib, might be used to overcome the limitations of radioligand therapy (RLT) with 177Lu-prostate-specific membrane antigen (PSMA) in metastasized castration-resistant prostate cancer. Here, we present 2 patients receiving such combination or sequential therapies. Methods: RLT was performed at 6- to 8-wk intervals after the patients either exhausted or were considered unfit for all approved conventional treatments. Patient 1 was on pembrolizumab for his squamous cell carcinoma of the skin, whereas patient 2 received RLT sequentially 4 wk after 3 mo of monotherapy with olaparib. Results: Both patients tolerated RLT without any significant hematotoxicity. Patient 2 showed a radiologic and biochemical response, whereas patient 1 achieved prostate-specific antigen stabilization after 3 therapy cycles. Conclusion: These cases indicate that RLT in combination with pembrolizumab or sequentially after olaparib might be well tolerated in single patients.